A blog about what is new (and old) in the world of active implantable medical devices

Home

AIMD Business

Boston Scientific Q1 2012 AIMD Results: CRM Down 10%, Neuromodulation 8% Up

Boston Scientific Q1 2012 AIMD Results: CRM Down 10%, Neuromodulation 8% Up

Published on April 20, 2012 by David Prutchi in AIMD Business, Boston Scientific

Boston Scientific Logo Yesterday Boston Scientific announced financial results for the first quarter ended March 31, 2012. Sales of Cardiac Rhythm Management devices were $501M vs. $559M for Q1 a year ago, or a decrease of 10%. Sales of Neuromodulation devices increased by 8% a year ago from $77M to $84M for Q1.

« St. Jude’s Reports Q1 20...

EnteroMedics Reports $123k Rev... »

Comments Off

The sole purpose of this page is to provide information on implantable devices to fellow engineers and scientists. The information on this website is not meant for patients. The views presented in these pages do not necessarily reflect the views of my past or current employers, collaborators and/or clients. This information does not supersede original manufacturer’s specifications nor constitute medical advice or advertisement. Trademarks and logos belong to their registered owners. I neither practice medicine nor provide medical services. I am an engineer, not a licensed physician, so I am not qualified to provide any kind of medical advice.

CAUTION: Many of the devices presented in this blog have NOT been cleared by US and other regulatory agencies for investigational and/or commercial use. Consult directly with the manufacturer for legal status and availability in your country. This material is intended for general educational purposes only.

April 2012
M	T	W	T	F	S	S
« Mar		May »
	1
2	3	4	5	6	7	8
9	10	11	12	13	14	15
16	17	18	19	20	21	22
23	24	25	26	27	28	29
30

HeartMate II Pocket Controller for Thoratec LVAD Gets U.S. Clearance May 17, 2013
Preventice BodyGuardian Continuous Patient Monitor Being Made Available in U.S. May 17, 2013
St. Jude’s ILUMIEN OPTIS PCI Optimization System with FFR, OCT Cleared in EU May 17, 2013
Telcare BGM Cellular-Based Glucometer Coming to Europe May 17, 2013
NinePoint’s NvisionVLE Tissue Imaging System Now Available in U.S. May 16, 2013
DESolve, a New Bioresorbable Coronary Scaffold from Elixir, Cleared in Europe May 16, 2013
New Laser System to Help Surgeons Drill Through Skull with Increased Safety May 15, 2013
Paper-Thin Device Performs Pulse Wave Monitoring in a Tiny Package May 15, 2013
Berkeley Brain Injury Detector Rivals CT in Spotting Cerebral Edema, Intracranial Hematomas May 15, 2013
Devon’s extriCARE Negative Pressure Wound Therapy CE Marked May 15, 2013

Can HIPAA Move Into the 21st Century? May 17, 2013
This Week in Devices [5/17/2013]: Dying Better, Scam Artists, and the End of Moore's Law May 17, 2013
Jolie Mastectomy Decision Resonates With Another Woman Who Has a Message for Implant Vendors May 17, 2013
Five Questions with Rick Valencia May 16, 2013
Cancer Diagnostics Firm Castle Biosciences Raises $1.5 Million May 16, 2013
Three Critical Factors for Force and Pressure Sensors in Infusion Pumps May 16, 2013
With No Approved Renal Denervation Products in U.S., Companies On to Next-Generation Devices May 15, 2013
Analyst: Worldwide CRM Market Improving, Will Be Down 2% This Year May 15, 2013
Per Capita Expenditure On Medical Devices Grew 33.9% Between 2006 and 2011 May 14, 2013
Imaging Speaks Loudly to Medical Device Testing May 14, 2013

A blog about what is new (and old) in the world of active implantable medical devices

Boston Scientific Q1 2012 AIMD Results: CRM Down 10%, Neuromodulation 8% Up

BUY MY BOOKS THROUGH AMAZON.COM

Blogroll

Important Disclaimer

Categories

Entries by Date

Archives

Medgadget

MDDI Online RSS Feeds

BUY MY BOOKS THROUGH AMAZON.COM

Meta

Meta